Epidemiology of cervical cancer and HPV infection in Asia and Oceania.
Asia
HPV
Oceania
cervical cancer
oropharyngeal cancer
screening
vaccination
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
08 Apr 2024
08 Apr 2024
Historique:
received:
25
03
2024
accepted:
27
03
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
8
4
2024
Statut:
aheadofprint
Résumé
Cancer will continue to be a major source of morbidity and mortality globally during the foreseeable future. Human papillomavirus (HPV)-related cancer is now a serious problem in both women and men. The most common HPV-related cancer is cervical cancer in females and oropharyngeal cancer in males. Eastern Africa has a high age-standardized incidence of HPV-related cancers, followed in order by Southern Africa, Central Africa, and then the rest of Africa. Among Asian and Oceania countries, Fiji, Papua New Guinea, Solomon Islands, Indonesia, Maldives, and Myanmar have extremely high age-standardized incidences and mortality. Oropharyngeal cancer is less common than cervical cancer, but the age-standardized incidence, for both females and males, is higher in Western Europe, Northern Europe, North America, and Australia/New Zealand. Oropharyngeal cancer incidence rates differ significantly from the rates of cervical cancer within the same countries. In Asia and Oceania, the incidence of oropharyngeal cancer is particularly high among females in Bhutan, Bangladesh, and Australia, and it is highest among males in Bangladesh, New Caledonia, Australia, and French Polynesia. To a certain extent, cervical cancer can be reduced through the development of cervical screening programs and improvements in screening uptake. On the other hand, for oropharyngeal cancer, as of yet, no effective means of cancer screening has been established. Widespread uptake of HPV vaccine will contribute to the reduction of HPV-related cancers in Asia and Oceania, but also in the rest of the world.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Health, Labour and Welfare
ID : 23EA1002
Informations de copyright
© 2024 The Authors. Journal of Obstetrics and Gynaecology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Obstetrics and Gynecology.
Références
Whiteman DC, Wilson LF. The fractions of cancer attributable to modifiable factors: a global review. Cancer Epidemiol. 2016;44:203–221.
Wilson LF, Antonsson A, Green AC, Jordan SJ, Kendall BJ, Nagle CM, et al. How many cancer cases and deaths are potentially preventable? Estimates for Australia in 2013. Int J Cancer. 2018;142(4):691–701.
Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68(1):31–54.
Brown KF, Rumgay H, Dunlop C, Ryan M, Quartly F, Cox A, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer. 2018;118(8):1130–1141.
Brenner DR, Friedenreich CM, Ruan Y, Poirier AE, Walter SD, King WD, et al. The burden of cancer attributable to modifiable risk factors in Canada: methods overview. Prev Med. 2019;122:3–8.
Park S, Jee SH, Shin HR, Park EH, Shin A, Jung KW, et al. Attributable fraction of tobacco smoking on cancer using population‐based nationwide cancer incidence and mortality data in Korea. BMC Cancer. 2014;14:406. https://doi.org/10.1186/1471-2407-14-406
Inoue M, Hirabayashi M, Abe SK, Katanoda K, Sawada N, Lin Y, et al. Burden of cancer attributable to modifiable factors in Japan in 2015. Glob Health Med. 2022;4(1):26–36.
Chen W, Xia C, Zheng R, Zhou M, Lin C, Zeng H, et al. Disparities by province, age, and sex in site‐specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. Lancet Glob Health. 2019;7(2):e257–e269.
Huang H, Hu XF, Zhao FH, Garland SM, Bhatla N, Qiao YL. Estimation of cancer burden attributable to infection in Asia. J Epidemiol. 2015;25(10):626–638. https://doi.org/10.2188/jea.JE20140215
Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC. Fifteen‐year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PloS One. 2012;7(4):e34779.
Nyitray AG, Lin HY, Fulp WJ, Chang M, Menezes L, Lu B, et al. The role of monogamy and duration of heterosexual relationships in human papillomavirus transmission. J Infect Dis. 2014;209(7):1007–1015.
Wu J, Xiao F, Zheng Y, Lin Y, Wang HL. Worldwide trend in human papillomavirus‐attributable cancer incidence rates between 1990 and 2012 and Bayesian projection to 2030. Cancer. 2021;127(17):3172–3182.
Cancer TODAY | IARC. https://gco.iarc.who.int
Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol. 2008;110(3 suppl 2):S4–S7.
Ueda Y, Enomoto T, Miyatake T, Ozaki K, Yoshizaki T, Kanao H, et al. Monoclonal expansion with integration of high‐risk type human papillomaviruses is an initial step for cervical carcinogenesis: association of clonal status and human papillomavirus infection with clinical outcome in cervical intraepithelial neoplasia. Lab Invest. 2003;83(10):1517–1527.
Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550–560.
Egawa N. Papillomaviruses and cancer: commonalities and differences in HPV carcinogenesis at different sites of the body. Int J Clin Oncol. 2023;28(8):956–964.
D'Souza G, Westra WH, Wang SJ, van Zante A, Wentz A, Kluz N, et al. Differences in the prevalence of human papillomavirus (HPV) in head and neck squamous cell cancers by sex, race, anatomic tumor site, and HPV detection method. JAMA Oncol. 2017;3(2):169–177.
Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer. 2009;124(10):2375–2383.
Zhang J, Zhang Y, Zhang Z. Prevalence of human papillomavirus and its prognostic value in vulvar cancer: a systematic review and meta‐analysis. PloS One. 2018;13:e0204162.
Ong SK, Abe SK, Thilagaratnam S, Haruyama R, Pathak R, Jayasekara H, et al. Towards elimination of cervical cancer ‐ human papillomavirus (HPV) vaccination and cervical cancer screening in Asian National Cancer Centers Alliance (ANCCA) member countries. Lancet Reg Health West Pac. 2023;39:100860.
Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low‐income and lower‐middle‐income countries. Lancet. 2020;395(10224):575–590.
Centers for Disease Control and Prevention. United States Cancer Statistics. Data Brief, No. 4 August 2018. https://www.cdc.gov/cancer/hpv/pdf/USCS-DataBrief-No4-August2018-508.pdf
Yagi A, Ueda Y, Kakuda M, Tanaka Y, Ikeda S, Matsuzaki S, et al. Epidemiologic and clinical analysis of cervical cancer using data from the population‐based Osaka Cancer Registry. Cancer Res. 2019;79(6):1252–1259.
Ikeda S, Ueda Y, Yagi A, Matsuzaki S, Kobayashi E, Kimura T, et al. HPV vaccination in Japan: what is happening in Japan? Expert Rev Vaccines. 2019;18(4):323–325.
Yagi A, Ueda Y, Kakuda M, Nakagawa S, Hiramatsu K, Miyoshi A, et al. Cervical cancer protection in Japan: where are we? Vaccines. 2021;9(11):1263.
Tanaka Y, Ueda Y, Egawa‐Takata T, Yagi A, Yoshino K, Kimura T. Outcomes for girls without HPV vaccination in Japan. Lancet Oncol. 2016;17(7):868–869.
Ueda Y, Yagi A, Ikeda S, Enomoto T, Kimura T. Beyond resumption of the Japanese Government's recommendation of the HPV vaccine. Lancet Oncol. 2018;19(12):1563–1564.